Neurotrope, Inc. Banner Image

Neurotrope, Inc.

  • Ticker NTRP
    Exchange NASDAQ More
  • Industry Biotechnology More
  • Sector Healthcare More
Neurotrope, Inc. Logo Image
  • 1-10 Employees
  • Based in New York City, New York
NBI is a clinical-stage biopharmaceutical company that has historically worked to develop novel therapies for neurodegenerative diseases. NBI has conducted clinical and preclinical studies of its lead therapeutic candidate, Bryostatin-1, in Alzheimer’s disease, and preclinical studies for rare diseases and brain injury, including Fragile X syndrome, multiple sclerosis, stroke, Niemann-PickMore Type C disease, Rett syndrome, and traumatic brain injury. The FDA has granted Orphan Drug Designation to NBI for Bryostatin-1 as a treatment for Fragile X syndrome. Bryostatin-1 has already undergone testing in more than 1,500 people in cancer studies, thus creating a large safety data base that will further inform clinical trial designs.
Neurotrope, Inc.

Most Recent Annual Report

Neurotrope, Inc.
MOST RECENT 2019 Form 10K